AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18276744 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 5 mg/day for 2 years followed by 10 mg/day for 1 year
Number of subjects: 200
Study 18276744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 16563890 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide 20 mcg/day
Number of subjects: 520
Study 16563890 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide 40 mcg/day
Number of subjects: 520
Study 16563890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 520
Study 14624219 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (20-40 microg) for induction of labor
Number of subjects: 0
Study 14624219 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol as a single agent
Number of subjects: 0
Study 14624219 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol for postpartum hemorrhage
Number of subjects: 0
Study 11192134 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin extended-release (once-daily for 14 days)
Number of subjects: 283
Study 11192134 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin immediate-release (twice-daily for 14 days)
Number of subjects: 283
Study 11192134 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin extended-release
Number of subjects: 283
Study 11192134 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin immediate-release
Number of subjects: 283
Study 9201523 — intervention group
Group type: EXPERIMENTAL
Intervention: S. boulardii 500 mg four times a day
Number of subjects: 128
Study 9201523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 9201523 — intervention group
Group type: EXPERIMENTAL
Intervention: S. boulardii 500 mg four times a day (after adjustment for risk factors)
Number of subjects: 128
Study 7835781 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 105
Study 7835781 — intervention group
Group type: COMPARATOR
Intervention: Control (no hormonal treatment)
Number of subjects: 105
Study 2972171 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol (200 mg, 3 times daily)
Number of subjects: 60
Study 2972171 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Medroxyprogesterone Acetate (MPA) (100 mg daily)
Number of subjects: 60
Study 2972171 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 29698440 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-modality exercise with additional mind-motor training (M4, n = 63)
Number of subjects: 127
Study 29698440 — intervention group
Group type: COMPARATOR
Intervention: Control group (balance, range of motion and breathing exercises [M2, n = 64])
Number of subjects: 127
Study 24239455 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep onset insomnia (SOI)
Number of subjects: 30
Study 24239455 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep maintenance insomnia (SMI)
Number of subjects: 30
Study 24239455 — intervention group
Group type: COMPARATOR
Intervention: Good sleepers (GS)
Number of subjects: 30
Study 22803412 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery plus Radiochemotherapy (surgery group)
Number of subjects: 104
Study 22803412 — intervention group
Group type: COMPARATOR
Intervention: Radiochemotherapy (conventional group)
Number of subjects: 104
Study 19628570 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen for 5 years
Number of subjects: 672
Study 19628570 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 5 years
Number of subjects: 672
Study 19628570 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen and Placebo
Number of subjects: 672
Study 18495848 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 302
Study 18495848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study 15815224 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse Case Manager (NCM) Model (Ward A)
Number of subjects: 145
Study 15815224 — intervention group
Group type: COMPARATOR
Intervention: Team nursing (Ward B)
Number of subjects: 145
Study 12799617 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics (risperidone, clozapine, olanzapine, quetiapine)
Number of subjects: 19
Study 12799617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 10513172 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactated Ringer's solution (LR group, n = 10)
Number of subjects: 20
Study 10513172 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetated Ringer's solution (AR group, n = 10)
Number of subjects: 20
Study 10513172 — intervention group
Group type: COMPARATOR
Intervention: Control (not applicable)
Number of subjects: 20
Study 7718072 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based injury prevention program in Harstad, implemented over three periods of 30 months each, with increasing preventive efforts.
Number of subjects: 0
Study 7718072 — intervention group
Group type: COMPARATOR
Intervention: Nonequivalent control city (Trondheim) with no active intervention.
Number of subjects: 0
Study 2119446 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN) with standard amino acids (1.5 g/kg/day)
Number of subjects: 28
Study 2119446 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocaloric isonitrogenous TPN with added branched‐chain amino acids
Number of subjects: 28
Study 2119446 — intervention group
Group type: COMPARATOR
Intervention: No nutritional support
Number of subjects: 28
Study 6987418 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine hydrochloride or amitriptyline hydrochloride
Number of subjects: 59
Study 6987418 — intervention group
Group type: COMPARATOR
Intervention: Control values (not specified)
Number of subjects: 59
Study 30737894 — intervention group
Group type: EXPERIMENTAL
Intervention: Short bouts of moderate physical activity (SBP) - two 25-minute bouts of moderate-intensity PA 6 d/wk
Number of subjects: 65
Study 30737894 — intervention group
Group type: COMPARATOR
Intervention: Long bout of moderate physical activity (LBP) - one 50-minute bout of moderate-intensity PA 6 d/wk
Number of subjects: 65
Study 28091696 — intervention group
Group type: EXPERIMENTAL
Intervention: Tin prefiltration (200 mAs)
Number of subjects: 100
Study 28091696 — intervention group
Group type: COMPARATOR
Intervention: Standard protocol without spectral shaping (25 mAs)
Number of subjects: 100
Study 25662039 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/d
Number of subjects: 217
Study 25662039 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/d
Number of subjects: 217
Study 25662039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study 23826157 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological treatment for 12 weeks
Number of subjects: 117
Study 22211210 — intervention group
Group type: EXPERIMENTAL
Intervention: Seclusion (N=12)
Number of subjects: 102
Study 22211210 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical restraint (N=14)
Number of subjects: 102
Study 22211210 — intervention group
Group type: COMPARATOR
Intervention: Seclusion (Cohort arm, N=48)
Number of subjects: 102
Study 22211210 — intervention group
Group type: COMPARATOR
Intervention: Mechanical restraint (Cohort arm, N=28)
Number of subjects: 102
Study 19125101 — intervention group
Group type: EXPERIMENTAL
Intervention: Resisted sprint (RS) training
Number of subjects: 15
Study 19125101 — intervention group
Group type: COMPARATOR
Intervention: Control group (no RS training)
Number of subjects: 15
Study 17361345 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training of elbow flexors and ankle dorsiflexors
Number of subjects: 65
Study 17361345 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (sustained-release, 8 mg bid)
Number of subjects: 65
Study 17361345 — intervention group
Group type: COMPARATOR
Intervention: Non-training (control group)
Number of subjects: 65
Study 15533268 — intervention group
Group type: EXPERIMENTAL
Intervention: Jarlsberg cheese (CH diet)
Number of subjects: 22
Study 15533268 — intervention group
Group type: COMPARATOR
Intervention: Butter + calcium caseinate (BC diet)
Number of subjects: 22
Study 15533268 — intervention group
Group type: COMPARATOR
Intervention: Butter + egg-white protein (BE diet)
Number of subjects: 22
Study 11345161 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDA simulator (active intervention)
Number of subjects: 0
Study 11345161 — intervention group
Group type: COMPARATOR
Intervention: Conventional educational methods (control group)
Number of subjects: 0
Study 9238064 — intervention group
Group type: COMPARATOR
Intervention: Lupron alone (gonadotropin-releasing hormone agonist)
Number of subjects: 0
Study 9238064 — intervention group
Group type: EXPERIMENTAL
Intervention: Lupron plus progesterone replacement
Number of subjects: 0
Study 9238064 — intervention group
Group type: EXPERIMENTAL
Intervention: Lupron plus estradiol replacement
Number of subjects: 0
Study 8116741 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (five injections of 5 mg during two weeks after surgery)
Number of subjects: 44
Study 8116741 — intervention group
Group type: COMPARATOR
Intervention: Control group (no 5-fluorouracil)
Number of subjects: 44
Study 8116741 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Number of subjects: 44
Study 3335990 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregestimil
Number of subjects: 6
Study 3335990 — intervention group
Group type: COMPARATOR
Intervention: Alfare
Number of subjects: 6
Study 30460936 — intervention group
Group type: EXPERIMENTAL
Intervention: Barbed sutures
Number of subjects: 84
Study 30460936 — intervention group
Group type: COMPARATOR
Intervention: Traditional sutures (Vicryl)
Number of subjects: 84
Study 28068186 — intervention group
Group type: EXPERIMENTAL
Intervention: PDT+chitosan 3 mg/mL
Number of subjects: 102
Study 28068186 — intervention group
Group type: EXPERIMENTAL
Intervention: PDT
Number of subjects: 102
Study 28068186 — intervention group
Group type: EXPERIMENTAL
Intervention: NaOCl (2.5%)
Number of subjects: 102
Study 28068186 — intervention group
Group type: COMPARATOR
Intervention: Positive control (no treatment)
Number of subjects: 102
Study 28068186 — intervention group
Group type: COMPARATOR
Intervention: Negative control (no inoculation, no treatment)
Number of subjects: 102
Study 25889633 — intervention group
Group type: EXPERIMENTAL
Intervention: sulphadoxine-pyrimethamine + artesunate (SP + AS)
Number of subjects: 912
Study 25889633 — intervention group
Group type: EXPERIMENTAL
Intervention: sulphadoxine-pyrimethamine + amodiaquine (SP + AQ)
Number of subjects: 912
Study 25889633 — intervention group
Group type: COMPARATOR
Intervention: sulphadoxine-pyrimethamine alone (SP)
Number of subjects: 912
Study 24351694 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (doses of at least 0.3 mg/kg)
Number of subjects: 10
Study 24351694 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (any dose)
Number of subjects: 10
Study 24351694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 21354596 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal graft placement (group 1)
Number of subjects: 20
Study 21354596 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined graft placement (group 2)
Number of subjects: 20
Study 18335008 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined tool approach using a battery-operated screwdriver and cutting tool as needed
Number of subjects: 84
Study 18335008 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 84
Study 16782922 — intervention group
Group type: EXPERIMENTAL
Intervention: Black cohosh (Cimicifuga racemosa 20 mg BID)
Number of subjects: 132
Study 16782922 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 12707092 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily sunscreen application (high-protection sunscreen applied every morning)
Number of subjects: 1621
Study 12707092 — intervention group
Group type: COMPARATOR
Intervention: Discretionary sunscreen use
Number of subjects: 1621
Study 12707092 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta carotene supplementation (30 mg/day)
Number of subjects: 1621
Study 12707092 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 1621
Study 10910476 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal IJV cannulation (≥ 1 cm above the cricoid level)
Number of subjects: 91
Study 10910476 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal IJV cannulation (≥ 1 cm below the cricoid level)
Number of subjects: 91
Study 10910476 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal IJV cannulation (≥ 1 cm above the cricoid level) after catheter removal
Number of subjects: 91
Study 10910476 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal IJV cannulation (≥ 1 cm below the cricoid level) after catheter removal
Number of subjects: 91
Study 8757560 — intervention group
Group type: EXPERIMENTAL
Intervention: Photographic screening tool for FAS facial phenotype
Number of subjects: 42
Study 1568574 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate start of steroid tapering (group A; n = 46)
Number of subjects: 147
Study 1568574 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued prednisolone treatment for 5 more weeks before tapering (group B; n = 50)
Number of subjects: 147
Study 1568574 — intervention group
Group type: COMPARATOR
Intervention: Already in endoscopic remission (group C; n = 40)
Number of subjects: 147
Study 6232035 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac, 600 mg/day
Number of subjects: 61
Study 6232035 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac, 800 mg/day
Number of subjects: 61
Study 6232035 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac, 1200 mg/day
Number of subjects: 61
Study 6232035 — intervention group
Group type: COMPARATOR
Intervention: Aspirin, 2600 mg/day
Number of subjects: 61
Study 6232035 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 31366643 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly sensitive acupoints group
Number of subjects: 716
Study 31366643 — intervention group
Group type: COMPARATOR
Intervention: Low/non-sensitive acupoints group
Number of subjects: 716
Study 31366643 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture group
Number of subjects: 716
Study 31366643 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 716
Study 31366643 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 716
Study 29408818 — intervention group
Group type: EXPERIMENTAL
Intervention: Atraumatic restorative treatment (ART)
Number of subjects: 50
Study 29408818 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraconservative treatment (UCT)
Number of subjects: 50
Study 29408818 — intervention group
Group type: COMPARATOR
Intervention: Conventional restorative treatment (CRT)
Number of subjects: 50
Study 29408818 — intervention group
Group type: COMPARATOR
Intervention: Nontreated open cavities
Number of subjects: 50
Study 26432508 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib (200 mg orally every 12 hours) with best supportive care (BSC)
Number of subjects: 550
Study 26432508 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib (150 mg orally every 24 hours) with best supportive care (BSC)
Number of subjects: 550
Study 25369006 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 48
Study 25369006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 22278333 — intervention group
Group type: EXPERIMENTAL
Intervention: Telcagepant 600 mg
Number of subjects: 60
Study 22278333 — intervention group
Group type: EXPERIMENTAL
Intervention: Telcagepant 900 mg
Number of subjects: 60
Study 22278333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 20176217 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastomotic connector
Number of subjects: 151
Study 20176217 — intervention group
Group type: COMPARATOR
Intervention: Hand-sutured grafts
Number of subjects: 151
Study 17378909 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 8 mg/h continuous IV infusion for 48 h after a bolus of 40 mg
Number of subjects: 164
Study 17378909 — intervention group
Group type: COMPARATOR
Intervention: Somatostatin 250 microg/h continuous IV infusion for 48 h after a bolus of 250 microg
Number of subjects: 164
Study 17378909 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 8 mg/h continuous IV infusion for 48 h
Number of subjects: 164
Study 17378909 — intervention group
Group type: COMPARATOR
Intervention: Somatostatin 250 microg/h continuous IV infusion for 48 h
Number of subjects: 164
Study 15972934 — intervention group
Group type: EXPERIMENTAL
Intervention: Low toenail chromium concentration (average 1.10 mug/g in cases)
Number of subjects: 684
Study 15972934 — intervention group
Group type: COMPARATOR
Intervention: Control group (average toenail chromium concentration 1.30 mug/g)
Number of subjects: 684
Study 11927145 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium lactate infusion
Number of subjects: 16
Study 11927145 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 16
Study 9798443 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery with anterior plate fixation
Number of subjects: 27
Study 9798443 — intervention group
Group type: COMPARATOR
Intervention: Surgery without anterior plate fixation
Number of subjects: 27
Study 7734253 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% halothane
Number of subjects: 23
Study 7734253 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8% isoflurane
Number of subjects: 23
Study 7734253 — intervention group
Group type: COMPARATOR
Intervention: Both agents
Number of subjects: 23
Study 2711281 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron and folate supplementation during pregnancy
Number of subjects: 0
Study 2711281 — intervention group
Group type: COMPARATOR
Intervention: Iron supplementation only during pregnancy
Number of subjects: 0
Study 2711281 — intervention group
Group type: COMPARATOR
Intervention: Control group (Iron only)
Number of subjects: 0
Study 30300054 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood flow restriction (BFR) therapy combined with low-resistance muscular training for 15 weeks
Number of subjects: 3
Study 30300054 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood flow restriction (BFR) therapy combined with low-resistance muscular training for 13 days
Number of subjects: 3
Study 30300054 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood flow restriction (BFR) therapy while immobilized in the early postoperative period
Number of subjects: 3
Study 30300054 — intervention group
Group type: COMPARATOR
Intervention: Low-resistance muscular training alone
Number of subjects: 3
Study 29059673 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered hypertonic saline (BHS)
Number of subjects: 36
Study 29059673 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (NSS)
Number of subjects: 36
Study 25491535 — intervention group
Group type: EXPERIMENTAL
Intervention: CM group (CM combined with FET)
Number of subjects: 168
Study 25491535 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopy group (hysteroscopic endometrial mechanical stimulation)
Number of subjects: 168
Study 25491535 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional FET)
Number of subjects: 168
Study 22832470 — intervention group
Group type: EXPERIMENTAL
Intervention: Error-augmentation training
Number of subjects: 20
Study 22832470 — intervention group
Group type: COMPARATOR
Intervention: Error-reduction training
Number of subjects: 20
Study 21597360 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery with fast track care (FT)
Number of subjects: 400
Study 21597360 — intervention group
Group type: EXPERIMENTAL
Intervention: Open surgery with fast track care (FT)
Number of subjects: 400
Study 21597360 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery with standard care
Number of subjects: 400
Study 21597360 — intervention group
Group type: COMPARATOR
Intervention: Open surgery with standard care
Number of subjects: 400
Study 19927096 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 600 U/kg subcutaneously once weekly starting 3 weeks before spinal surgery plus standard of care for blood conservation
Number of subjects: 680
Study 19927096 — intervention group
Group type: COMPARATOR
Intervention: Standard of care alone
Number of subjects: 680
Study 19927096 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 680
Study 19927096 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 680
Study 17031007 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitosan (six 500 mg capsules per day)
Number of subjects: 150
Study 17031007 — intervention group
Group type: COMPARATOR
Intervention: Control group (weight loss programs of their choice)
Number of subjects: 150
Study 17031007 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (PLA)
Number of subjects: 150
Study 14677527 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (32 mg once daily)
Number of subjects: 1013
Study 14677527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1013
Study 11051260 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin 40 mg/m2 followed by Docetaxel 50 mg/m2
Number of subjects: 25
Study 11051260 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 70 mg/m2 followed by Doxorubicin 50 mg/m2
Number of subjects: 25
Study 11051260 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel followed by Doxorubicin
Number of subjects: 25
Study 11051260 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin followed by Docetaxel
Number of subjects: 25
Study 11051260 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin 50 mg/m2 followed by Docetaxel 60 mg/m2
Number of subjects: 25
Study 9176438 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine spray
Number of subjects: 120
Study 9176438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 9176438 — intervention group
Group type: COMPARATOR
Intervention: Lignocaine spray and Placebo
Number of subjects: 120
Study 1439067 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril + hydrochlorothiazide (CAP + HCTZ) 25 mg once a day
Number of subjects: 80